Wyeth LLC et al. v. Teva Canada Limited

Drug: venlafaxine

The Supreme Court of Canada dismissed Wyeth’s application for leave to appeal the decision of the Federal Court of Appeal (FCA) which permitted ratiopharm’s s. 8 proceeding, claiming damages from Wyeth, to continue after it amalgamated with Teva. Teva has a licence from Wyeth for the product. Our summary of the FCA decision can be found here.